Design Therapeutics Modifies RESTORE-FA Trial, Initiates DT-818 Dosing, Reports Q2 Cash of $207.4M
DSGN has more than doubled off its 52-week low of $3.76.
Summary
Design Therapeutics provided a clinical update on its lead Friedreich ataxia program, modifying the RESTORE-FA trial based on positive four-week data reported in May. The trial will now use endogenous blood FXN protein change as the primary endpoint, explore a dose above 1 mpk, and enroll 10 patients in a 12-week cohort, with registrational plans expected in Q4 2026 and 12-week data in Q1 2027. Additionally, dosing has begun in a Phase 1 MAD trial of DT-818 for myotonic dystrophy type 1, while FECD data is delayed to 2027 due to a supply issue. Q2 financials show a net loss of $20.2M and cash of $207.4M, providing runway beyond 12 months. The trial modifications and pipeline progress are incremental but meaningful for a $760M market cap biotech, though the extended timelines and lack of new efficacy data keep the update from being a major catalyst.
At the time of this announcement, DSGN was trading at $12.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $760.7M. The 52-week trading range was $3.76 to $17.25. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.